(Press-News.org) LA JOLLA, Calif., November 21, 2011 – The trouble with most anti-cancer therapies is that they are lethal to most cells in the body, not just cancer cells. As a result, patients experience side effects like nausea, increased susceptibility to infection, and increased risk of developing secondary cancers later in life. Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) are developing techniques to deliver cancer drugs directly to tumors, increasing their effectiveness and decreasing collateral damage. In a study published the week of November 21 in the Proceedings of the National Academy of Sciences of the USA, a team led by Michiko Fukuda, Ph.D. coupled a cancer drug to a small protein called IF7, which is specifically attracted to the blood vessels that feed tumors. When administered in a mouse model of human colon cancer, IF7 carried the drug directly to tumors, where it suppressed growth at low dosages and with no apparent side effects. These findings suggest that IF7 is an efficient drug delivery vehicle that could be further exploited to target a variety of anti-cancer therapeutics where they're needed most, without harming other tissues.
"We can cure terminal stage mice with very large tumors without any side effects simply by giving them this drug coupled with IF7," said Dr. Fukuda, professor in Sanford-Burnham's National Cancer Institute (NCI)-designated Cancer Center and corresponding author of the study.
Carbohydrates coat the surface of every cell in the body. They—and the proteins that bind them—play important roles in many cellular processes, including tumor formation and cancer metastasis. However, unlike genes or proteins, carbohydrates are difficult to synthesize in the lab. To get around that hurdle, Dr. Fukuda and her team tested a collection of short proteins (called peptides) in the hopes of finding some that can mimic carbohydrates and inhibit carbohydrate-dependent metastasis. IF7 was one of the "winning" peptides. Upon further investigation, Dr. Fukuda's team found that IF7 works because it binds annexin 1, a carbohydrate-binding protein that is found in particularly high levels on the surfaces of blood vessels that feed tumors.
In this study, the researchers coupled IF7 with a fluorescent probe and administered it to mice bearing human colon tumors. They watched as, within minutes, the probe lit up the tumors. Next, they coupled IF7 with SN-38, a potent anti-cancer drug. They also engineered the tumors to glow, so they could measure them after daily injections with IF7/SN-38. Tumors in treated mice shrank dramatically while tumor size in mock-treated mice was unchanged. It's worth noting that the amount of SN-38 the mice received in this study was only one-seventh the amount a previous study used to treat tumors in mice. Perhaps for that reason, blood tests showed no signs of side effects in IF7/SN-38-treated mice.
"Although we tested colon tumors in this study, theoretically any tumor that induces expression of annexin 1 in blood vessels would work with this system—it just depends on what kind of drug it's paired with," said Minoru Fukuda, Ph.D., professor in Sanford-Burnham's National Cancer Institute (NCI)-designated Cancer Center and co-author of the study.
Given its extremely specific tumor-targeting activity, the authors conclude that IF7 may represent a clinically relevant vehicle for anti-cancer drugs. Next, they hope to further prepare this technology for clinical trials in humans.
INFORMATION:
This research was funded by the National Cancer Institute, part of the National Institutes of Health, the Department of Defense, and Susan G. Komen for the Cure. Co-authors include Shingo Hatakeyama, Sanford-Burnham; Kazuhiro Sugihara, Hamamatsu University School of Medicine; Toshiaki K. Shibata, Sanford-Burnham; Jun Nakayama, Shinshu University Graduate School of Medicine; Tomoya O. Akama, Sanford-Burnham; Naoaki Tamura, Sanford-Burnham; Shuk-Man Wong, Sanford-Burnham; Andrey A. Bobkov, Sanford-Burnham; Yutaka Takano, Sanford-Burnham; Chikara Ohyama, Hirosaki University School of Medicine; Minoru Fukuda, Sanford-Burnham; and Michiko N. Fukuda, Sanford-Burnham.
For more information about Sanford-Burnham research, visit our blog or follow us on Twitter.
About Sanford-Burnham Medical Research Institute
Sanford-Burnham Medical Research Institute is dedicated to discovering the fundamental molecular causes of disease and devising the innovative therapies of tomorrow. Sanford-Burnham, with operations in California and Florida, is one of the fastest-growing research institutes in the country. The Institute ranks among the top independent research institutions nationally for NIH grant funding and among the top organizations worldwide for its research impact. From 1999 – 2009, Sanford-Burnham ranked #1 worldwide among all types of organizations in the fields of biology and biochemistry for the impact of its research publications, defined by citations per publication, according to the Institute for Scientific Information. According to government statistics, Sanford-Burnham ranks #2 nationally among all organizations in capital efficiency of generating patents, defined by the number of patents issued per grant dollars awarded.
Sanford-Burnham utilizes a unique, collaborative approach to medical research and has established major research programs in cancer, neurodegeneration, diabetes, and infectious, inflammatory, and childhood diseases. The Institute is especially known for its world-class capabilities in stem cell research and drug discovery technologies. Sanford-Burnham is a nonprofit public benefit corporation. For more information, please visit www.sanfordburnham.org.
Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Sanford-Burnham scientists show that coupling a tumor-homing peptide and an anti-cancer drug drastically reduces tumors in a mouse model of colon cancer, with no apparent side effects; technique could be applied to many types of cancer
2011-11-22
ELSE PRESS RELEASES FROM THIS DATE:
New breast cancer screening guidelines released
2011-11-22
New breast cancer screening guidelines for women at average risk of breast cancer, published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110334.pdf, recommend no routine mammography screening for women aged 40-49 and extend the screening interval from every 2 years, which is current clinical practice, to every 2 to 3 years for women aged 50-74. The guidelines also recommend against routine clinical breast exam and breast self-examination in asymptomatic women.
The guidelines, aimed at physicians and policy-makers, ...
DesignPractica Expands eCommerce and Custom CMS Services
2011-11-22
DesignPractica has been creating and maintaining custom websites for small businesses in Greater Vancouver area for several years. Now, in addition to offering WordPress, Django and Google Application Engine websites, DesignPractica will also provide support and development services with all top open-source and hosted eCommerce and CMS systems, such as Magento, Drupal, Volusion, Shopify, Satchmo and others, for small, medium and large businesses in the greater Vancouver region.
DesignPractica has a successful history of helping local manufacturers, farmers, restaurants ...
More than one-quarter of Canadian adults projected to have hypertension in 2012/13
2011-11-22
Hypertension in Canada is increasing, and it is projected that more than one-quarter of Canadian adults will be diagnosed with hypertension by 2012/13, according to a study in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj101863.pdf. Older women were more likely to be diagnosed with high blood pressure compared with men, and people in the Atlantic provinces had the highest rates of hypertension.
Canadian researchers looked at data on 26 million adults aged 20 years and over between 1998 and 2007/08 to ...
Families report adverse events in hospitalized children not tracked by health-care providers
2011-11-22
Families of hospitalized children can provide valuable information about adverse events relating to their children's care that complements information documented by health care professionals, states a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110393.pdf.
Hospitals in Canada have instituted systems to encourage reporting of adverse events — things that may negatively affect the recovery or health of a patient — in patient care. In pediatrics, it is estimated that 1% of children in hospital ...
NIH researchers identify key proteins of inner ear transduction channel
2011-11-22
National Institutes of Health-funded researchers have identified two proteins that may be the key components of the long-sought after mechanotransduction channel in the inner ear—the place where the mechanical stimulation of sound waves is transformed into electrical signals that the brain recognizes as sound. The findings are published in the Nov. 21 online issue of The Journal of Clinical Investigation.
The study used mice in which two genes, TMC1 and TMC2, have been deleted. The researchers revealed a specific functional deficit in the mechanotransduction channels ...
October Issue of Proceedings of the IEEE Presents Most Comprehensive Metamaterials Analysis Ever Assembled
2011-11-22
The future of the metamaterials field shows great promise for achieving exotic new functions according to October's Proceedings of the IEEE, the most highly-cited general-interest journal in electrical engineering and computer science, approaching its 100th year of publication in 2012. Entitled "Metamaterials: Fundamentals and Applications in the Microwave and Optical Regimes," the 16-article issue, written by internationally renowned leaders in the field is packed with innovative research reports on potential new functions and insights that could impact many ...
Implanted neurons, grown in the lab, take charge of brain circuitry
2011-11-22
MADISON -- Among the many hurdles to be cleared before human embryonic stem cells can achieve their therapeutic potential is determining whether or not transplanted cells can functionally integrate into target organs or tissues.
Writing today (Monday, Nov. 21) in the Proceedings of the National Academy of Sciences, a team of Wisconsin scientists reports that neurons, forged in the lab from blank slate human embryonic stem cells and implanted into the brains of mice, can successfully fuse with the brain's wiring and both send and receive signals.
Neurons are specialized, ...
Boosting the aged immune response to flu virus
2011-11-22
As people age, their immune system becomes less robust. This makes them more susceptible to serious and frequently life-threatening infections with viruses that affect the respiratory tract such as influenza A virus (IAV). Stanley Perlman and colleagues, at the University of Iowa, Iowa City, have now identified a new immune system defect in aged mice that makes them more susceptible than young mice to developing severe clinical disease upon infection with respiratory viruses such as IAV. Importantly, they were able to reverse the defect by inhibiting the immune molecule ...
Conservatoryinfo.co.uk Introduces New Redesigned Website
2011-11-22
For businesses, having a signature look is important for brand awareness; however, when the evolving times call for a major change, Conservatoryinfo.co.uk knows how to do it right. After years of maintaining the same look of their website, Conservatoryinfo.co.uk implements a major redesign to improve its functionality, interface, and overall performance for users and search engines.
The new website provides an easy flow of information combined with appealing graphics that was launched last September 2011. It debuted with new features and built-in SEO elements in accordance ...
BRAF addiction of thyroid cancers makes them therapeutically vulnerable
2011-11-22
Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine (RAI). A team of researchers led by James Fagin, at Memorial Sloan-Kettering Cancer Center, New York, has now identified a way to potentially exploit the expression of BRAF by such cancers for therapeutic purposes.
Despite the prevalence of BRAF mutations in papillary ...
LAST 30 PRESS RELEASES:
New research boosts future whooping cough vaccines
Mechanistic understanding could enable better fast-charging batteries
No bones about it: new details about skeletal cell aging revealed
UNM scientists discover how nanoparticles of toxic metal used in MRI scans infiltrate human tissue
UMaine research examines best methods for growing Atlantic sea scallops
Medical cannabis could speed recovery, especially at community recovery homes
Study assesses U.S. image amid weakening of democracy
Two scientific researchers to receive 2025 Ralph L. Sacco Scholarships for Brain Health
Researchers improve chemical reaction that underpins products from foods to fuels
Texas Tech to develop semiconductor power devices through $6 million grant
Novel genomic screening tool enables precision reverse-engineering of genetic programming in cells
Hot Schrödinger cat states created
How cells repair their power plants
Oxygen is running low in inland waters—and humans are to blame
ACP’s Best Practice Advice addresses use of cannabis, cannabinoids for chronic noncancer pain
Beyond photorespiration: A systematic approach to unlocking enhanced plant productivity
How a small number of mutations can fuel outbreaks of western equine encephalitis virus
Exposure to wildfire smoke linked with worsening mental health conditions
Research uncovers hidden spread of one of the most common hospital-associated infections
Many older adults send their doctors portal messages, but who pays?
Fine particulate matter from 2020 California wildfires and mental health–related emergency department visits
Gender inequity in institutional leadership roles in US academic medical centers
Pancreatic cells ‘remember’ epigenetic precancerous marks without genetic sequence mutations
Rare combination of ovarian tumors found in one patient
AI-driven clinical recommendations may aid physician decision making to improve quality of care
Artificial intelligence has potential to aid physician decisions during virtual urgent care
ACP and Annals of Internal Medicine present breaking scientific news at ACP’s Internal Medicine Meeting 2025
New study reveals polymers with flawed fillers boost heat transfer in plastics
Signs identified that precede sudden arrhythmic death syndrome in young people
Discovery of bacteria's defence against viruses becomes a piece of the puzzle against resistance
[Press-News.org] Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatmentSanford-Burnham scientists show that coupling a tumor-homing peptide and an anti-cancer drug drastically reduces tumors in a mouse model of colon cancer, with no apparent side effects; technique could be applied to many types of cancer